Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan method could catch 20% more hidden cancers

NCT ID NCT06527027

Diagnosis Sponsor: Copernicus Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares three methods for reading CT and MRI scans of lymph nodes to see which best detects cancer. The new method, LN-RADS, may find small metastases that current guidelines miss. Researchers will enroll 1,000 people with known or suspected cancer who need a lymph node biopsy. The goal is to see if LN-RADS is more accurate than the standard RECIST 1.1 and the newer Node-RADS systems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If LN-RADS works better, doctors could detect more lymph node metastases, leading to more accurate cancer staging and better treatment decisions.
What could go wrong
This is a diagnostic comparison study, not a treatment trial. Even if LN-RADS is more accurate, it may not improve patient outcomes or be adopted widely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * diagnosed or suspected cancer, * planned lymph node biopsy or lymphadenectomy, * planned or performed CT/MRI covering an area of the body with lymph nodes, - verified histopathologically or cytologically, * informed consent to participate in the study. Exclusion Criteria: * non-diagnostic CT/MRI images of lymph nodes due to reasons such as movement artifacts, artifacts from metal elements and any other factors that do not allow for proper assessment of the nodes, * inconclusive histopathological or cytological results, which do not allow the nodes to be classified into one of two groups - benign or malignant.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymph node metastasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lymph node neoplasm Lymphadenopathy Lymphatic Metastasis metastatic malignant neoplasm in the lymph nodes Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymph node metastasis Lymph node neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Copernicus Memorial Hospital

    RECRUITING

    Lodz, 93-513, Poland

  • Doradztwo i Zarządzanie w Opiece Zdrowotnej A.K. Sp.z o.o

    ACTIVE_NOT_RECRUITING

    Warsaw, Poland

  • Independent Public Healthcare Centre (SPZOZ) , University Clinical Hospital No. 2 of the Medical University of Łódź

    ACTIVE_NOT_RECRUITING

    Lodz, Poland

  • Maria Skłodowska-Curie National Research Institute of Oncology - National Research Institute

    ACTIVE_NOT_RECRUITING

    Krakow, Poland

  • Maria Skłodowska-Curie National Research Institute of Oncology - National Research Institute

    ACTIVE_NOT_RECRUITING

    Warsaw, Poland

  • Professor Orłowski Hospital in Warsaw , Independent Public Healthcare Centre

    ACTIVE_NOT_RECRUITING

    Warsaw, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.